Aleksander Prejbisz Selected Research

3-methoxytyramine (methoxytyramine)

1/2022	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.
10/2020	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
5/2020	Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?
8/2017	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
4/2017	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.
4/2014	Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions.
1/2014	Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aleksander Prejbisz Research Topics

Disease

28	Hypertension (High Blood Pressure) 05/2022 - 01/2003
24	Paraganglioma (Paragangliomas) 01/2022 - 02/2008
18	Pheochromocytoma 01/2022 - 02/2008
14	Neoplasms (Cancer) 01/2022 - 04/2015
11	Hyperaldosteronism (Conn Syndrome) 01/2022 - 01/2003
5	Adenoma (Adenomas) 01/2020 - 01/2003
3	Obstructive Sleep Apnea 01/2021 - 10/2011
3	Hyperplasia 01/2018 - 01/2003
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017 - 06/2003
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 06/2003
2	Cardiomyopathies (Cardiomyopathy) 01/2021 - 12/2014
2	Pathologic Constriction (Stenosis) 01/2021 - 01/2021
2	Essential Hypertension 01/2020 - 06/2014
2	Renal Insufficiency (Renal Failure) 01/2016 - 01/2012
2	Heart Failure 12/2014 - 01/2013
2	Sleep Apnea Syndromes (Sleep Apnea) 01/2013 - 10/2011
2	Glucose Intolerance 01/2013 - 10/2011
2	Renal Artery Obstruction (Renal Artery Stenosis) 01/2013 - 06/2003
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022
1	Adrenocortical Carcinoma 01/2022
1	Adrenal incidentaloma 01/2022
1	Hypertrophy 12/2020
1	Atrial Fibrillation 09/2020
1	Vascular Remodeling 01/2020
1	Obesity 01/2019
1	Hyperlipidemias (Hyperlipidemia) 01/2019
1	Weight Gain 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Hypoxia (Hypoxemia) 04/2017
1	Cardiomegaly (Heart Hypertrophy) 01/2017
1	Malignant Hypertension 01/2016
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2016
1	Hemorrhage 01/2016
1	Papilledema 01/2016
1	Mood Disorders (Mood Disorder) 01/2016
1	Abdominal Obesity 03/2015
1	Albuminuria 02/2015
1	Pulmonary Edema 12/2014
1	Heart Arrest (Cardiac Arrest) 12/2014
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2014
1	Polycystic Kidney Diseases (Polycystic Kidney Disease) 03/2014
1	Parkinson Disease (Parkinson's Disease) 01/2014

Drug/Important Bio-Agent (IBA)

17	CatecholaminesIBA 01/2022 - 11/2011
10	NormetanephrineIBA 01/2022 - 03/2013
10	MetanephrineIBA 12/2020 - 03/2013
9	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 01/2003
7	3-methoxytyramine (methoxytyramine)IBA 01/2022 - 01/2014
6	Succinate Dehydrogenase (Fumarate Reductase)IBA 01/2022 - 02/2008
6	AldosteroneIBA 01/2022 - 01/2003
3	SteroidsIBA 01/2022 - 01/2020
3	Adrenergic Agents (Adrenergic Drugs)IBA 01/2022 - 04/2017
3	Dopamine (Intropin)FDA LinkGeneric 08/2017 - 03/2013
3	Glucose (Dextrose)FDA LinkGeneric 03/2015 - 10/2011
2	SaltsIBA 05/2022 - 01/2017
2	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2022 - 01/2020
2	Phosphotransferases (Kinase)IBA 11/2020 - 04/2017
2	Retinaldehyde (Retinal)IBA 01/2020 - 01/2016
2	ReninIBA 01/2020 - 01/2014
2	3-Iodobenzylguanidine (Iobenguane)IBA 03/2019 - 01/2015
2	Hormones (Hormone)IBA 01/2019 - 01/2013
2	Epinephrine (Adrenaline)FDA LinkGeneric 01/2019 - 02/2015
2	CalciumIBA 01/2017 - 01/2013
2	Mineralocorticoid Receptor AntagonistsIBA 01/2016 - 01/2015
2	Cystatin CIBA 02/2015 - 01/2010
1	Dietary SodiumIBA 05/2022
1	lipoprotein cholesterolIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	FibrinIBA 01/2022
1	Cytidine Monophosphate (CMP)IBA 01/2021
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	4- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA 12/2020
1	CorticosteroneIBA 01/2020
1	Cortodoxone (11 Deoxycortisol)IBA 01/2020
1	GlucocorticoidsIBA 01/2020
1	Contraceptive Agents (Contraceptives)IBA 01/2019
1	Angiotensin II Type 1 Receptor BlockersIBA 01/2017
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2017
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017
1	Drug CombinationsIBA 01/2017
1	EnzymesIBA 09/2016
1	mahuang-tangIBA 01/2016
1	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2016
1	Hydralazine (Apresoline)FDA LinkGeneric 01/2016
1	SynaptophysinIBA 04/2015
1	Keratins (Keratin)IBA 04/2015
1	ChromograninsIBA 04/2015
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 04/2015
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2015
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2015
1	AlbuminsIBA 06/2014
1	Levodopa (L Dopa)FDA LinkGeneric 01/2014

Therapy/Procedure

7	Therapeutics 10/2021 - 01/2003
7	Denervation 01/2021 - 10/2011
7	Adrenalectomy 12/2020 - 01/2016
6	Catheters 01/2021 - 01/2011
4	Sympathectomy (Sympathectomies) 01/2021 - 01/2011
1	Renal Dialysis (Hemodialysis) 01/2021
1	Drug Therapy (Chemotherapy) 01/2017
1	Cesarean Section (Caesarean Section) 12/2014